NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Authors:
Top Cited Papers
Open Access
- 1 November 2022
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 20 (11) , 1204-1214
Abstract
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in theKITorPDGFRAgenes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.Keywords
This publication has 78 references indexed in Scilit:
- Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor EraClinical Cancer Research, 2012
- Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinibCancer Chemotherapy and Pharmacology, 2011
- Succinate Dehydrogenase-Deficient GISTsAmerican Journal of Surgical Pathology, 2011
- Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutationsProceedings of the National Academy of Sciences, 2010
- Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug ResistanceClinical Cancer Research, 2009
- A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal TumorsClinical Cancer Research, 2009
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsProceedings of the National Academy of Sciences, 2009
- Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumorsGenes, Chromosomes and Cancer, 2008
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998